• In June 2026, Organon reported that the US FDA approved a supplemental Biologics License Application expanding TOFIDENCE, a tocilizumab biosimilar to ACTEMRA, to treat CAR T cell-induced severe cytokine release syndrome and certain hospitalized COVID-19 patients aged 2 years and older.
• This makes TOFIDENCE the first tocilizumab biosimilar available in the US across a broad range of autoimmune and acute inflammatory indications, potentially reinforcing Organon’s focus on expanding its biosimilars portfolio and patient access.
• We’ll now examine how TOFIDENCE’s expanded indications in cytokine release syndrome and severe COVID-19 may influence Organon’s broader investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Organon Investment Narrative Recap

To own Organon today, you largely need to believe that its pivot toward higher margin assets like biosimilars can offset pressure on aging brands and funding-sensitive women’s health products. The TOFIDENCE label expansion reinforces the biosimilar story, but it does not clearly change the near term focus on the proposed Sun Pharmaceutical acquisition or the key risk of ongoing generic and pricing pressure on legacy therapies.

The most relevant recent announcement here is Organon’s European approval for POHERDY, its pertuzumab biosimilar. Together with TOFIDENCE’s broader US indications, this highlights how the biosimilars portfolio is becoming a more meaningful part of the investment case at a time when established brands face loss of exclusivity and pricing headwinds that could weigh on revenue stability.

Yet investors should be aware that Organon’s reliance on mature products and exposure to pricing pressure could still...

Organon's narrative projects $6.3 billion revenue and $986.8 million earnings by 2029. This implies fairly flat yearly revenue growth and about a $740.8 million earnings increase from $246.0 million today.

Uncover how Organon's forecasts yield a $11.25 fair value, a 16% downside to its current price.

Exploring Other Perspectives

Before this approval, the most optimistic analysts were already assuming revenue of about US$6.6 billion and US$1.0 billion in earnings by 2028, so if you share their view that biosimilars can offset legacy product erosion, TOFIDENCE’s expanded label might strengthen that thesis, but these projections also show how far expectations can stretch and why it is worth comparing different scenarios for Organon’s future.

Explore 6 other fair value estimates on Organon - why the stock might be worth over 6x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Organon research is our analysis highlighting 3 key rewards and 5 important warning signs that could impact your investment decision.
• Our free Organon research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Organon's overall financial health at a glance.

Curious About Other Options?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.